血液ベースバイオマーカーの世界市場レポート 2025年

血液ベースバイオマーカーの市場規模は今後数年で急成長が見込まれます。2029年にはCAGR12.4％で415億5,000万米ドルに成長します。予測期間中の成長は、バイオマーカー分析におけるAIと機械学習の拡大、疾患の早期発見に対する需要の高まり、遠隔医療と遠隔診断の成長、慢性疾患の有病率の増加、消費者の健康意識の高まりが牽引するとみられます。この期間の主な動向には、AIを活用したバイオマーカー探索、リキッドバイオプシーの進展、マルチオミクスの統合、ポイントオブケア（POC）検査機器の開発、次世代シーケンサー（NGS）の革新などが含まれます。

心血管疾患の有病率の増加は、血液ベースバイオマーカー市場の成長を促進すると予想されます。心血管疾患は、冠動脈疾患、心不全、脳卒中などの心臓や血管に影響を及ぼす疾患を包含し、食生活の乱れや肥満率の上昇などの危険因子により、より一般的になりつつあります。血液ベースバイオマーカーは、血液中の測定可能な物質を通して、病気の進行、リスク評価、治療反応に関する貴重な情報を提供することにより、これらの病気の診断とモニタリングにおいて重要な役割を果たしています。2024年9月に国立生物工学情報センター（National Center for Biotechnology Information）が行った世界の健康調査イニシアチブでは、2025～2050年までに心血管疾患患者が90％増加し、心血管疾患による死亡者数は2050年までに3,560万人に達すると予測されています。このような心血管疾患の罹患率の上昇が、血液ベースバイオマーカー市場の成長に寄与しています。

血液ベースバイオマーカー市場の主要企業は、アルツハイマー病などの診断に役立つ高精度の血液バイオマーカー検査などの技術革新に注力しています。これらの検査は、血液中の特定のバイオマーカーを利用して、高い精度と信頼性で健康状態を検出またはモニタリングします。例えば、米国のライフサイエンス企業であるQuanterix社は、2023年10月、認知機能障害を有する成人のアルツハイマー病の診断を医師が支援するために設計された高精度の血液バイオマーカー検査であるLucentAD p-Tau 217検査を発表しました。この検査は、スレオニン217でリン酸化されたタウタンパク質（p-Tau 217）を測定するもので、アルツハイマー病の病態、特に脳内のアミロイド蓄積と強く関連しています。LucentAD p-Tau 217検査は、90％以上の精度を提供し、厳格な診断基準を満たすもので、単独ではなく、他の診断ツールと並行して使用されることを意図しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、貿易戦争と関税、そしてコロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の血液ベースバイオマーカーのPESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の血液ベースバイオマーカー市場：成長率分析
• 世界の血液ベースバイオマーカー市場の実績：規模と成長、2019～2024年
• 世界の血液ベースバイオマーカー市場の予測：規模と成長、2024～2029年、2034年
• 世界の血液ベースバイオマーカー総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の血液ベースバイオマーカー市場：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 遺伝子バイオマーカー
• タンパク質バイオマーカー
• 代謝バイオマーカー
• 細胞ベースバイオマーカー
• エピジェネティックバイオマーカー
• 世界の血液ベースバイオマーカー市場：技術別、実績と予測、2019～2024年、2024～2029年、2034年
• 次世代シーケンシング
• ポリメラーゼ連鎖反応
• 免疫測定
• 質量分析
• その他
• 世界の血液ベースバイオマーカー市場：用途別、実績と予測、2019～2024年、2024～2029年、2034年
• がん
• 心血管疾患
• 神経疾患
• 免疫疾患
• その他
• 世界の血液ベースバイオマーカー市場：エンドユーザー別、実績と予測、2019～2024年、2024～2029年、2034年
• 病院・クリニック
• 診断検査室
• 研究・学術機関
• その他
• 世界の血液ベースバイオマーカー市場：遺伝子バイオマーカーのサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 遺伝子バイオマーカー
• タンパク質バイオマーカー
• 代謝バイオマーカー
• 細胞ベースバイオマーカー
• エピジェネティックバイオマーカー
• 世界の血液ベースバイオマーカー市場：タンパク質バイオマーカーのサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 酵素
• ホルモン
• サイトカイン
• 腫瘍マーカー
• 急性期タンパク質
• 世界の血液ベースバイオマーカー市場：代謝バイオマーカーのサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 脂質プロファイル
• アミノ酸レベル
• 血糖値・乳酸値
• 有機酸
• 代謝物パネル
• 世界の血液ベースバイオマーカー市場：細胞ベースバイオマーカーのサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 循環腫瘍細胞（CTC）
• 免疫細胞プロファイリング
• 幹細胞
• 血小板
• 内皮細胞
• 世界の血液ベースバイオマーカー市場：エピジェネティックバイオマーカーのサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• デオキシリボ核酸（DNA）のメチル化パターン
• ヒストン修飾
• 非コードリボ核酸（RNA）
• クロマチンアクセシビリティ
• エピジェネティック酵素活性

第7章 地域別・国別分析

• 世界の血液ベースバイオマーカー市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
• 世界の血液ベースバイオマーカー市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 血液ベースバイオマーカー市場：競合情勢
• 血液ベースバイオマーカー市場：企業プロファイル
  • Siemens Healthineers AG Overview, Products and Services, Strategy and Financial Analysis
  • Agilent Technologies Inc Overview, Products and Services, Strategy and Financial Analysis
  • Eisai Co Ltd Overview, Products and Services, Strategy and Financial Analysis
  • Sysmex Corporation Overview, Products and Services, Strategy and Financial Analysis
  • Exact Sciences Corporation Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Guardant Health
• Quanterix Corporation
• Illumina Inc
• QIAGEN NV
• GENFIT
• Foundation Medicine Inc
• Adaptive Biotechnologies Corporation
• GRAIL LLC
• Biodesix Inc
• Cleveland Diagnostics Inc
• Creative Diagnostics
• Epigenomics AG
• C2N Diagnostics
• Diadem srl
• Proteomedix AG

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 血液ベースバイオマーカー市場2029年：新たな機会を提供する国
• 血液ベースバイオマーカー市場2029年：新たな機会を提供するセグメント
• 血液ベースバイオマーカー市場2029年：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Blood-based biomarkers are substances in the blood that can be measured to indicate the presence, progression, or response to a disease. They are primarily used for early detection, helping to personalize treatment plans and monitor treatment effectiveness with minimal invasiveness.

These biomarkers can be categorized into several types, including genetic, protein, metabolic, cell-based, and epigenetic biomarkers. Genetic biomarkers, which are based on DNA or RNA, identify genetic variations, mutations, or expression patterns linked to specific diseases or treatment responses. They are utilized in various advanced technologies, such as next-generation sequencing, polymerase chain reaction, immunoassays, and mass spectrometry. These biomarkers play a critical role in diagnosing and monitoring diseases such as cancer, cardiovascular conditions, neurological disorders, and immunological diseases. Key users of these biomarkers include hospitals, clinics, diagnostic labs, research institutes, and other healthcare providers.

The blood-based biomarkers market research report is one of a series of new reports from The Business Research Company that provides blood-based biomarkers market statistics, including the blood-based biomarkers industry global market size, regional shares, competitors with the blood-based biomarkers market share, detailed blood-based biomarkers market segments, market trends, and opportunities, and any further data you may need to thrive in the blood-based biomarkers industry. This blood-based biomarkers market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The blood-based biomarkers market size has grown rapidly in recent years. It will grow from $23.13 billion in 2024 to $26.06 billion in 2025 at a compound annual growth rate (CAGR) of 12.6%. The growth observed in the past can be attributed to the increasing global incidence of cancer, a higher adoption of personalized medicine, more funding in biomarker research, a rise in clinical trials involving biomarkers, and an increase in the approval of companion diagnostics.

The blood-based biomarkers market size is expected to see rapid growth in the next few years. It will grow to $41.55 billion in 2029 at a compound annual growth rate (CAGR) of 12.4%. The growth during the forecast period is expected to be driven by the expansion of AI and machine learning in biomarker analysis, a higher demand for early disease detection, the growth of telemedicine and remote diagnostics, the increasing prevalence of chronic diseases, and greater health awareness among consumers. Key trends during this period will include AI-driven biomarker discovery, advancements in liquid biopsy, integration of multi-omics, development of point-of-care (POC) testing devices, and innovations in next-generation sequencing (NGS).

The increasing prevalence of cardiovascular diseases is expected to drive the growth of the blood-based biomarkers market. Cardiovascular diseases, which encompass disorders affecting the heart and blood vessels such as coronary artery disease, heart failure, and stroke, are becoming more common due to risk factors such as poor diet and rising obesity rates. Blood-based biomarkers play a crucial role in diagnosing and monitoring these diseases by offering valuable information on disease progression, risk assessment, and treatment response through measurable substances in the blood. A global health research initiative by the National Center for Biotechnology Information in September 2024 projected a 90% increase in cardiovascular disease cases from 2025 to 2050, with cardiovascular deaths expected to reach 35.6 million by 2050. This rising incidence of cardiovascular diseases is contributing to the market growth for blood-based biomarkers.

Leading companies in the blood-based biomarkers market are focusing on technological innovations, such as high-accuracy blood biomarker tests, to assist in diagnosing diseases such as Alzheimer's disease. These tests use specific biomarkers in the blood to detect or monitor health conditions with high precision and reliability. For example, in October 2023, Quanterix, a US-based life sciences company, introduced the LucentAD p-Tau 217 test, a high-accuracy blood biomarker test designed to help physicians diagnose Alzheimer's disease in adults with cognitive impairment. The test measures phosphorylated tau protein at threonine 217 (p-Tau 217), which is strongly linked to Alzheimer's pathology, particularly amyloid buildup in the brain. The LucentAD p-Tau 217 test provides over 90% accuracy, fulfilling stringent diagnostic criteria, and is meant to be used alongside other diagnostic tools rather than independently.

In December 2023, Danaher, a US-based provider of diagnostic, life sciences, and environmental solutions, acquired Abcam for $5.7 billion. This acquisition allows Danaher to enhance its life sciences portfolio by incorporating Abcam's leading protein consumables and research tools. Abcam, a UK-based life sciences company, specializes in the development and distribution of research tools, including antibodies, assays, and reagents.

Major players in the blood based biomarkers market are Siemens Healthineers AG, Agilent Technologies Inc, Eisai Co Ltd, Sysmex Corporation, Exact Sciences Corporation, Guardant Health, Quanterix Corporation, Illumina Inc, QIAGEN NV, GENFIT, Foundation Medicine Inc, Adaptive Biotechnologies Corporation, GRAIL LLC, Biodesix Inc, Cleveland Diagnostics Inc, Creative Diagnostics, Epigenomics AG, C2N Diagnostics, Diadem srl, Proteomedix AG.

North America was the largest region in the blood-based biomarkers market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in blood-based biomarkers report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the blood-based biomarkers market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The blood-based biomarkers market consists of revenues earned by entities by providing services such as clinical trial services, sample collection and biobanking services, custom biomarker assay development, data analysis and interpretation services, companion diagnostics services, point-of-care testing services, and regulatory and compliance support services. The market value includes the value of related goods sold by the service provider or included within the service offering. The blood-based biomarkers market includes sales of diagnostic kits, reagents, assay platforms, analyzers, and related consumables. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Blood Based Biomarkers Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on blood based biomarkers market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for blood based biomarkers ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The blood based biomarkers market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Genetic Biomarkers; Protein Biomarkers; Metabolic Biomarkers; Cell-Based Biomarkers; Epigenetic Biomarkers
• 2) By Technology: Next-Generation Sequencing; Polymerase Chain Reaction; Immunoassays; Mass Spectrometry; Other Technologies
• 3) By Application: Cancer; Cardiovascular Diseases; Neurological Diseases; Immunological Diseases; Other Applications
• 4) By End Users: Hospitals And Clinics; Diagnostic Laboratories; Research And Academic Institutes; Other End Users
• Subsegments:
• 1) By Genetic Biomarkers: Deoxyribonucleic Acid (DNA) Mutations; Ribonucleic Acid (RNA) Expression Profiles; Single Nucleotide Polymorphisms (SNPs); Copy Number Variations (CNVs); Gene Fusions
• 2) By Protein Biomarkers: Enzymes; Hormones; Cytokines; Tumor Markers; Acute Phase Proteins
• 3) By Metabolic Biomarkers: Lipid Profiles; Amino Acid Levels; Glucose And Lactate Levels; Organic Acids; Metabolite Panels
• 4) By Cell-Based Biomarkers: Circulating Tumor Cells (CTCs); Immune Cell Profiling; Stem Cells; Platelets; Endothelial Cells
• 5) By Epigenetic Biomarkers: Deoxyribonucleic Acid (DNA) Methylation Patterns; Histone Modifications; Non-Coding Ribonucleic Acid (RNA); Chromatin Accessibility; Epigenetic Enzyme Activity
• Companies Mentioned: Siemens Healthineers AG; Agilent Technologies Inc; Eisai Co Ltd; Sysmex Corporation; Exact Sciences Corporation
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Blood Based Biomarkers Market Characteristics

3. Blood Based Biomarkers Market Trends And Strategies

4. Blood Based Biomarkers Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Blood Based Biomarkers Growth Analysis And Strategic Analysis Framework

• 5.1. Global Blood Based Biomarkers PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Blood Based Biomarkers Market Growth Rate Analysis
• 5.4. Global Blood Based Biomarkers Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Blood Based Biomarkers Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Blood Based Biomarkers Total Addressable Market (TAM)

6. Blood Based Biomarkers Market Segmentation

• 6.1. Global Blood Based Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Genetic Biomarkers
• Protein Biomarkers
• Metabolic Biomarkers
• Cell-Based Biomarkers
• Epigenetic Biomarkers
• 6.2. Global Blood Based Biomarkers Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Next-Generation Sequencing
• Polymerase Chain Reaction
• Immunoassays
• Mass Spectrometry
• Other Technologies
• 6.3. Global Blood Based Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cancer
• Cardiovascular Diseases
• Neurological Diseases
• Immunological Diseases
• Other Applications
• 6.4. Global Blood Based Biomarkers Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals And Clinics
• Diagnostic Laboratories
• Research And Academic Institutes
• Other End Users
• 6.5. Global Blood Based Biomarkers Market, Sub-Segmentation Of Genetic Biomarkers, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Genetic Biomarkers
• Protein Biomarkers
• Metabolic Biomarkers
• Cell-Based Biomarkers
• Epigenetic Biomarkers
• 6.6. Global Blood Based Biomarkers Market, Sub-Segmentation Of Protein Biomarkers, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Enzymes
• Hormones
• Cytokines
• Tumor Markers
• Acute Phase Proteins
• 6.7. Global Blood Based Biomarkers Market, Sub-Segmentation Of Metabolic Biomarkers, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Lipid Profiles
• Amino Acid Levels
• Glucose And Lactate Levels
• Organic Acids
• Metabolite Panels
• 6.8. Global Blood Based Biomarkers Market, Sub-Segmentation Of Cell-Based Biomarkers, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Circulating Tumor Cells (CTCs)
• Immune Cell Profiling
• Stem Cells
• Platelets
• Endothelial Cells
• 6.9. Global Blood Based Biomarkers Market, Sub-Segmentation Of Epigenetic Biomarkers, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Deoxyribonucleic Acid (DNA) Methylation Patterns
• Histone Modifications
• Non-Coding Ribonucleic Acid (RNA)
• Chromatin Accessibility
• Epigenetic Enzyme Activity

7. Blood Based Biomarkers Market Regional And Country Analysis

• 7.1. Global Blood Based Biomarkers Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Blood Based Biomarkers Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Blood Based Biomarkers Market

• 8.1. Asia-Pacific Blood Based Biomarkers Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Blood Based Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Blood Based Biomarkers Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Blood Based Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Blood Based Biomarkers Market

• 9.1. China Blood Based Biomarkers Market Overview
• 9.2. China Blood Based Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Blood Based Biomarkers Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Blood Based Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Blood Based Biomarkers Market

• 10.1. India Blood Based Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Blood Based Biomarkers Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Blood Based Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Blood Based Biomarkers Market

• 11.1. Japan Blood Based Biomarkers Market Overview
• 11.2. Japan Blood Based Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Blood Based Biomarkers Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Blood Based Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Blood Based Biomarkers Market

• 12.1. Australia Blood Based Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Blood Based Biomarkers Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Blood Based Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Blood Based Biomarkers Market

• 13.1. Indonesia Blood Based Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Blood Based Biomarkers Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Blood Based Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Blood Based Biomarkers Market

• 14.1. South Korea Blood Based Biomarkers Market Overview
• 14.2. South Korea Blood Based Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Blood Based Biomarkers Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Blood Based Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Blood Based Biomarkers Market

• 15.1. Western Europe Blood Based Biomarkers Market Overview
• 15.2. Western Europe Blood Based Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Blood Based Biomarkers Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Blood Based Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Blood Based Biomarkers Market

• 16.1. UK Blood Based Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Blood Based Biomarkers Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Blood Based Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Blood Based Biomarkers Market

• 17.1. Germany Blood Based Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Blood Based Biomarkers Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Blood Based Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Blood Based Biomarkers Market

• 18.1. France Blood Based Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Blood Based Biomarkers Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Blood Based Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Blood Based Biomarkers Market

• 19.1. Italy Blood Based Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Blood Based Biomarkers Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Blood Based Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Blood Based Biomarkers Market

• 20.1. Spain Blood Based Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Blood Based Biomarkers Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Blood Based Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Blood Based Biomarkers Market

• 21.1. Eastern Europe Blood Based Biomarkers Market Overview
• 21.2. Eastern Europe Blood Based Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Blood Based Biomarkers Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Blood Based Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Blood Based Biomarkers Market

• 22.1. Russia Blood Based Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Blood Based Biomarkers Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Blood Based Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Blood Based Biomarkers Market

• 23.1. North America Blood Based Biomarkers Market Overview
• 23.2. North America Blood Based Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Blood Based Biomarkers Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Blood Based Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Blood Based Biomarkers Market

• 24.1. USA Blood Based Biomarkers Market Overview
• 24.2. USA Blood Based Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Blood Based Biomarkers Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Blood Based Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Blood Based Biomarkers Market

• 25.1. Canada Blood Based Biomarkers Market Overview
• 25.2. Canada Blood Based Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Blood Based Biomarkers Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Blood Based Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Blood Based Biomarkers Market

• 26.1. South America Blood Based Biomarkers Market Overview
• 26.2. South America Blood Based Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Blood Based Biomarkers Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Blood Based Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Blood Based Biomarkers Market

• 27.1. Brazil Blood Based Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Blood Based Biomarkers Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Blood Based Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Blood Based Biomarkers Market

• 28.1. Middle East Blood Based Biomarkers Market Overview
• 28.2. Middle East Blood Based Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Blood Based Biomarkers Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Blood Based Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Blood Based Biomarkers Market

• 29.1. Africa Blood Based Biomarkers Market Overview
• 29.2. Africa Blood Based Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Blood Based Biomarkers Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Blood Based Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Blood Based Biomarkers Market Competitive Landscape And Company Profiles

• 30.1. Blood Based Biomarkers Market Competitive Landscape
• 30.2. Blood Based Biomarkers Market Company Profiles
  • 30.2.1. Siemens Healthineers AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Agilent Technologies Inc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Eisai Co Ltd Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Sysmex Corporation Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Exact Sciences Corporation Overview, Products and Services, Strategy and Financial Analysis

31. Blood Based Biomarkers Market Other Major And Innovative Companies

• 31.1. Guardant Health
• 31.2. Quanterix Corporation
• 31.3. Illumina Inc
• 31.4. QIAGEN NV
• 31.5. GENFIT
• 31.6. Foundation Medicine Inc
• 31.7. Adaptive Biotechnologies Corporation
• 31.8. GRAIL LLC
• 31.9. Biodesix Inc
• 31.10. Cleveland Diagnostics Inc
• 31.11. Creative Diagnostics
• 31.12. Epigenomics AG
• 31.13. C2N Diagnostics
• 31.14. Diadem srl
• 31.15. Proteomedix AG

32. Global Blood Based Biomarkers Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Blood Based Biomarkers Market

34. Recent Developments In The Blood Based Biomarkers Market

35. Blood Based Biomarkers Market High Potential Countries, Segments and Strategies

• 35.1 Blood Based Biomarkers Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Blood Based Biomarkers Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Blood Based Biomarkers Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer